Reuters: Global Markets: FDA demands OvaScience apply for product approval; shares slump

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Mobile Game Development Course Learn how to create awesome HTML5 games that run on iPhone, iPad, Android and Desktop! Sign up today for this $99 online course. From our sponsors

FDA demands OvaScience apply for product approval; shares slump Sep 10th 2013, 22:49 Tue Sep 10, 2013 6:49pm EDT (Reuters) - OvaScience Inc (OVAS.O), a developer of infertility treatments, said it plans to suspend enrollment in a U.S. study testing its lead product after regulators sought an application for the product's approval, sending the company's stock down 44 percent. OvaScience's Augment is being developed as a low-risk human cellular and tissue-based product (HCT/P), which requires no regulatory approval for testing or marketing. The product is being tested in a human study to help improve egg quality and increase the success of in-vitro fertilization. However, the company said the FDA questioned the status of Augment as an HCT/P in a letter sent on Friday. The agency also sought an investigational new drug application (IND) for Augment. An IND is reviewed by the FDA to check if a product is safe for research subjects. It is a precursor to clinical testing of drugs that are eventually pitched to the FDA for marketing approval. The company said it expects to have further talks with the FDA and present details on Augment's qualifications as an HCT/P. In a similar regulatory intervention on September 4, the FDA said MiMedx Group Co's (MDXG.O) human-tissue derived products did not have appropriate regulatory approvals and needed to be deemed safe and effective by the agency before being sold. OvaScience now plans to start sites for a study of Augment in select countries outside of the United States in 2014. The Cambridge, Massachusetts-based company's shares fell to a low of $8.30 in extended trading. They closed at $14.27 on the Nasdaq on Tuesday. (Reporting by Zeba Siddiqui in Bangalore) Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions